Association of acamprosate versus gabapentinoids with hospitalization and total mortality in alcohol use disorder
Journal of Hospital Medicine · 2025
DOI: 10.1002/jhm.70033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hospital Medicine, 2025. Verfasst von Raj Shah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Education Services, Orlando VA Healthcare System, Orlando, Florida, USA. Hauptthemen laut MEDLINE: Acamprosate, Gabapentin, Hospitalization, Alcoholism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Importance Alcohol use disorder (AUD) significantly increases hospitalizations and death. US Food and Drug Administration (FDA)‐approved medications for AUD are underutilized. Gabapentinoids are not FDA‐approved for AUD but are frequently prescribed by physicians.
Objective
To examine the association of acamprosate and gabapentinoids on healthcare utilization and total mortality in patients with AUD.
Methods
Two propensity score (PS)‐matched retrospective cohort studies.
Participants
Veterans diagnosed with AUD (years 2003–2021) initiating acamprosate or gabapentinoids in an AUD‐related encounter and not on chronic opioid therapy (AUD‐cohort). Another PS‐cohort of veterans who were hospitalized for AUD diagnoses (AUD‐admission cohort). Subgroup analysis included people with chronic obstructive lung diseases, opioid use, and age categories. Main Outcomes Co‐primary outcomes were admission for alcohol withdrawal (AW‐admission) and annual rate of acute care events. Secondary outcome was total mortality.
Results
We matched 16,072 pairs of acamprosate and gabapentinoid users in AUD‐cohort. AW‐admission occurred in 35.4% of the acamprosate users and 30.0% of the gabapentinoid users (odds ratio [OR]: 1.28, 95% confidence interval [95% CI]: 1.22–1.34). Annual rate of acute care events in acamprosate and gabapentinoid users were 1.84 and 1.64, respectively (coefficient of regression [ β ]: 0.20, 95% CI: 0.12–0.28). There was no difference in total mortality (hazard ratio: 0.96, 95% CI: 0.91–1.005). In subgroup analysis, acamprosate use was associated with less total mortality in subgroups of people using opioids and older than 60 years.
Conclusion
Gabapentinoids are associated with reduced AW‐admission and lower annual rates of acute care events compared to acamprosate. Gabapentinoids may offer a viable alternative for AUD in carefully selected populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Education Services, Orlando VA Healthcare System, Orlando, Florida, USA.
- University of Central Florida/HCA Florida Healthcare, Greater Orlando, Florida, USA.
- Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, Florida, USA.
- Pharmacy Services, Orlando VA Healthcare System, Orlando, Florida, USA.
Zitieren
APA
Shah, R., Zelneronok, K. A., Henriquez, R., & Mansi, I. A. (2025). Association of acamprosate versus gabapentinoids with hospitalization and total mortality in alcohol use disorder. Journal of Hospital Medicine. https://doi.org/10.1002/jhm.70033
Vancouver
Shah R, Zelneronok KA, Henriquez R, Mansi IA. Association of acamprosate versus gabapentinoids with hospitalization and total mortality in alcohol use disorder. Journal of Hospital Medicine. 2025. doi:10.1002/jhm.70033
BibTeX
@article{Shah2025,
author = {Shah, Raj and Zelneronok, Kirsten A and Henriquez, Richard and Mansi, Ishak A},
title = {Association of acamprosate versus gabapentinoids with hospitalization and total mortality in alcohol use disorder},
journal = {Journal of Hospital Medicine},
year = {2025},
doi = {10.1002/jhm.70033}
}
EUVIMED